Skip to content
DataLookout
Menu

NCT07907354

Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Objective Response Rate (ORR)
Timeframe: every 2 cycles (each cycle is 21 or 28 days depending on chosen chemotherapy), up to disease progression or 24 months

Secondary (5)

Progression-Free Survival
Time to Progression (TTP)
Overall Survival (OS)
Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
Clinical Benefit Rate (CBR)

Arms and interventions

Apatinib + Physician's Choice ChemotherapyExperimental

Low-dose apatinib mesylate (250 mg orally once daily) combined with physician's choice single-agent chemotherapy (TPC). TPC is selected by investigator based on prior therapy, with XLD (capecitabine, vinorelbine, taxane, etc.) as priority. Treatment continues until disease progression or unacceptable toxicity.

Drugs: Apatinib mesylate, Physician's choice chemotherapy